The separation of the Rx business is set to better enable the company’s unique asset to capitalise on its platform of differentiated generic pharmaceutical products. Credit: SimonQ.

-Perrigo has announced plans to separate its Prescription Pharmaceuticals (Rx) business following a recent strategic portfolio review.

Expected to be completed during the second half of next year, the separation of the Rx business will better enable the company’s unique asset to capitalise on its platform of differentiated generic pharmaceutical products.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will also allow Perrigo to focus on expanding its consumer business.

Perrigo’s Rx business serves patients and health systems with ‘extended topicals’ medications. Its portfolio includes topical generic medicines in multiple dosage forms, including creams, foams, mousses, gels, liquids and inhalable products.

The company’s Board of Directors will consider all value-enhancing options, including a possible tax-efficient separation to shareholders, a sale or merger.

“Perrigo’s consumer and Rx platforms are both well positioned, but they are also navigating divergent industry dynamics.”

Perrigo Board of Directors chairman Rolf Classon said: “Perrigo’s consumer and Rx platforms are both well positioned, but they are also navigating divergent industry dynamics with unique strategic, financial and operational opportunities and requirements.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We intend to begin the preparations for a separation of the Rx business to shareholders as we continue to analyse numerous value-enhancing options including a possible tax-efficient separation to shareholders, a sale or merger.”

Perrigo chief executive officer Uwe Roehrhoff said: “Today’s announcement to separate the Rx business enables management to focus on expanding our leading consumer businesses while unlocking potential value for shareholders.

“Committing our energy and capital to the healthcare needs of consumers and our retail and pharmacy partners better positions Perrigo to drive long-term growth. We look forward to providing a comprehensive update on our consumer businesses on a conference call scheduled for September 25, 2018.”

Perrigo noted that it has been subject to certain limitations related to separating its businesses since the acquisition of Elan.

The limitations are set to expire in December this year.

The separation of its Rx business is expected to be completed in the second half of 2019. The company has engaged Barclays’ as its lead financial adviser in the separation.